Andrzej Hellmann
About
Andrzej Hellmann is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine.
According to data from OpenAlex, Andrzej Hellmann has authored 58 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Genetics, 29 papers in Hematology and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Andrzej Hellmann's work include Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (20 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Andrzej Hellmann is often cited by papers focused on Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (20 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Andrzej Hellmann collaborates with scholars based in Poland, United States and Germany. Andrzej Hellmann's co-authors include Tadeusz Robak, Jerzy Hołowiecki, Geoffrey Chan, Jiřı́ Mayer, Jan Walewski, Jørgen Holm Petersen, Lars Møller Pedersen, Nedjad Losic, Mimi Folden Flensburg and Ole Gadeberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.
In The Last Decade
Andrzej Hellmann
56 papers receiving 3.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrzej Hellmann Poland | 23 | 1.8k | 1.5k | 1.3k | 711 | 589 | 58 | 3.1k | ||
| Monica Bocchia Italy | 28 | 1.1k 0.6× | 1.3k 0.9× | 850 0.7× | 964 1.4× | 1.0k 1.7× | 179 | 2.9k | ||
| Stefan Faderl United States | 26 | 1.7k 1.0× | 2.0k 1.3× | 1.0k 0.8× | 743 1.0× | 548 0.9× | 115 | 3.6k | ||
| Preetesh Jain United States | 32 | 2.2k 1.2× | 1.4k 1.0× | 1.5k 1.2× | 846 1.2× | 1.0k 1.7× | 181 | 3.7k | ||
| Marı́a Rozman Spain | 30 | 2.1k 1.2× | 1.4k 0.9× | 1.6k 1.3× | 910 1.3× | 631 1.1× | 128 | 3.6k | ||
| E Montserrat Spain | 30 | 1.4k 0.8× | 769 0.5× | 1.8k 1.4× | 820 1.2× | 1.0k 1.8× | 97 | 3.0k | ||
| H. Kantarjian United States | 29 | 2.1k 1.2× | 2.4k 1.7× | 676 0.5× | 481 0.7× | 637 1.1× | 120 | 3.9k | ||
| Carolyn Owen Canada | 21 | 2.1k 1.2× | 989 0.7× | 1.8k 1.4× | 782 1.1× | 702 1.2× | 99 | 3.1k | ||
| Stephen Opat Australia | 25 | 1.4k 0.8× | 570 0.4× | 1.7k 1.4× | 562 0.8× | 980 1.7× | 158 | 2.7k | ||
| Francesca Romana Mauro Italy | 31 | 2.4k 1.3× | 739 0.5× | 1.7k 1.3× | 1.3k 1.9× | 630 1.1× | 157 | 3.3k | ||
| Ester Orlandi Italy | 26 | 1.3k 0.7× | 1.2k 0.8× | 771 0.6× | 218 0.3× | 546 0.9× | 95 | 2.4k |
Countries citing papers authored by Andrzej Hellmann
Since
Specialization
Citations
This map shows the geographic impact of Andrzej Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrzej Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrzej Hellmann more than expected).
Fields of papers citing papers by Andrzej Hellmann
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrzej Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrzej Hellmann. The network helps show where Andrzej Hellmann may publish in the future.
Co-authorship network of co-authors of Andrzej Hellmann
This figure shows the co-authorship network connecting the top 25 collaborators of Andrzej Hellmann. A scholar is included among the top collaborators of Andrzej Hellmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrzej Hellmann. Andrzej Hellmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jakóbkiewicz‐Banecka, Joanna, et al.. (2025). In Vitro models of leukemia development: the role of very small leukemic stem-like cells in the cellular transformation cascade. Frontiers in Cell and Developmental Biology. 12. 1463807–1463807.
2.
Jakóbkiewicz‐Banecka, Joanna, et al.. (2024). Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential. Molecules. 29(17). 4280–4280.
3.
Ross, David M., Tamás Masszi, María Teresa Gómez‐Casares, et al.. (2018). Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Journal of Cancer Research and Clinical Oncology. 144(5). 945–954.
4.
Cortes, Jörge E., Florian H. Heidel, Andrzej Hellmann, et al.. (2018). Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 33(2). 379–389.
5.
Bussel, James B., Donald M. Arnold, Jiřı́ Mayer, et al.. (2018). Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials. American Journal of Hematology. 93(7). 921–930.
6.
Robak, Tadeusz, Andrzej Hellmann, Janusz Kłoczko, et al.. (2016). Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 176(4). 618–628.
7.
Mital, Andrzej, Witold Prejzner, Renata Świątkowska−Stodulska, & Andrzej Hellmann. (2015). Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera – retrospective analysis of 142 consecutive cases. Thrombosis Research. 136(4). 754–757.
8.
Hoffmann, Verena, Michele Baccarani, Doris Lindoerfer, et al.. (2013). The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 27(10). 2016–2022.
9.
Valentino, Leonard A., Vasily Mamonov, Andrzej Hellmann, et al.. (2011). A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis. 10(3). 359–367.
10.
Coiffier, Bertrand, Stéphane Leprêtre, Lars Møller Pedersen, et al.. (2007). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 111(3). 1094–1100.
11.
Kowal, Małgorzata, Anna Dmoszyńska, Krzysztof Lewandowski, et al.. (2004). Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukaemia (B-CLL)—Polish Multicentre Study. Leukemia & lymphoma. 45(6). 1159–1165.
12.
Hus, Iwona, Anna Dmoszyńska, Marek Hus, et al.. (2004). An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer. 91(11). 1873–1879.
13.
Czyż, Jarosław, Richard Szydlo, Andrzej Hellmann, et al.. (2004). Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplantation. 33(12). 1225–1229.
14.
Wrzesień‐Kuś, Agata, Tadeusz Robak, Ewa Lech‐Marańda, et al.. (2003). A multicenter, open, non‐comparative, phase II study of the combination of cladribine (2‐chlorodeoxyadenosine), cytarabine, and G‐CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG). European Journal Of Haematology. 71(3). 155–162.
15.
Robak, Tadeusz, Jerzy Z. Błoński, Joanna Góra‐Tybor, et al.. (2003). Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. European Journal of Cancer. 40(3). 383–389.
16.
Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2002). Re‐treatment with cladribine‐based regimens in relapsed patients with B‐cell chronic lymphocytic leukemia. European Journal Of Haematology. 69(1). 27–36.
17.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, Andrzej Hellmann, & L Konopka. (1997). Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2‐chlorodeoxyadenosine (cladribine). European Journal Of Haematology. 58(2). 109–113.
18.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, et al.. (1997). 2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases. European Journal Of Haematology. 59(4). 216–220.
19.
Robak, Tadeusz, Maria Błasińska-Morawiec, E Krykowski, et al.. (1996). 2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia. Leukemia & lymphoma. 22(1-2). 107–111.
20.
Hellmann, Andrzej, et al.. (1991). Glutathiones-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias. Medical Oncology and Tumor Pharmacotherapy. 8(1). 35–38.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Monica Bocchia Breakdown of academic impact, for papers by Stefan Faderl Breakdown of academic impact, for papers by Preetesh Jain Breakdown of academic impact, for papers by Marı́a Rozman Breakdown of academic impact, for papers by E Montserrat Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Carolyn Owen Breakdown of academic impact, for papers by Stephen Opat Breakdown of academic impact, for papers by Francesca Romana Mauro Breakdown of academic impact, for papers by Ester Orlandi